NASDAQ
BridgeBio Pharma, Inc. (BBIO)
♥ 608 Thanks from members
BridgeBio Pharma, Inc. (BBIO) demonstrates robust market sentiment, anchored by Attruby's strong commercial uptake in ATTR-CM, a recent $390 million equity raise, and a late-stage pipeline featuring catalysts like encaleret, though weighed down by valuation and concentration risks.